Turley Stephen D, Dietschy John M
Department of Internal Medicine, The University of Texas Southwestern Medical Center at Dallas, TX 75390-8887, USA.
Curr Opin Lipidol. 2003 Jun;14(3):233-40. doi: 10.1097/00041433-200306000-00002.
Cholesterol absorption is a selective process in that plant sterols and other non-cholesterol sterols are absorbed poorly or not at all. Recent research on the sterol efflux pumps adenosine triphosphate-binding cassette transporter G5 and adenosine triphosphate-binding cassette transporter G8 has not only provided an explanation for this selectivity, but also, together with the discovery of a new class of cholesterol absorption inhibitor, has yielded new insights into the mechanisms that potentially regulate the flux of cholesterol across the enterocyte. This review discusses these recent developments and their importance to the regulation of whole body cholesterol homeostasis.
Adenosine triphosphate-binding cassette transporters G5/8 regulate plant sterol absorption and also the secretion into bile of cholesterol and non-cholesterol sterols. Loss of adenosine triphosphate-binding cassette transporter G5/8 function results in sitosterolemia. Ezetimibe, a novel, potent and selective inhibitor of cholesterol absorption which is effective in milligram doses, lowers plasma plant sterol concentrations in sitosterolemic subjects, thus suggesting that this drug might be inhibiting the activity of a putative sterol permease in the brush border membrane of the enterocyte that actively facilitates the uptake of cholesterol as well as other non-cholesterol sterols.
Intestinal cholesterol absorption represents a major route for the entry of cholesterol into the body's miscible pools and therefore can potentially impact the plasma LDL-cholesterol concentration. The combined use of agents that inhibit the absorption and synthesis of cholesterol provides a powerful new approach to the prevention and treatment of atherosclerosis.
胆固醇吸收是一个选择性过程,植物甾醇和其他非胆固醇甾醇吸收不良或根本不被吸收。最近对甾醇流出泵三磷酸腺苷结合盒转运体G5和三磷酸腺苷结合盒转运体G8的研究不仅为这种选择性提供了解释,而且与一类新型胆固醇吸收抑制剂的发现一起,对潜在调节胆固醇穿过肠细胞流量的机制有了新的认识。本综述讨论了这些最新进展及其对全身胆固醇稳态调节的重要性。
三磷酸腺苷结合盒转运体G5/8调节植物甾醇吸收以及胆固醇和非胆固醇甾醇向胆汁中的分泌。三磷酸腺苷结合盒转运体G5/8功能丧失导致谷甾醇血症。依泽替米贝是一种新型、强效且选择性的胆固醇吸收抑制剂,毫克剂量即可起效,可降低谷甾醇血症患者的血浆植物甾醇浓度,因此表明该药物可能抑制肠细胞刷状缘膜中一种假定的甾醇通透酶的活性,该通透酶可积极促进胆固醇以及其他非胆固醇甾醇的摄取。
肠道胆固醇吸收是胆固醇进入人体混合池的主要途径,因此可能影响血浆低密度脂蛋白胆固醇浓度。联合使用抑制胆固醇吸收和合成的药物为动脉粥样硬化的预防和治疗提供了一种强有力的新方法。